Osaka, Japan

Naohide Kanemoto

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Naohide Kanemoto. Retrieved from https://idiyas.com/inventor/naohide-kanemoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Naohide Kanemoto: Innovator in Cyanotriazole Compounds

Introduction

Naohide Kanemoto is a notable inventor based in Osaka, Japan, recognized for his contribution to pharmaceutical innovations. He holds a patent that has the potential to advance treatments for conditions related to metabolism and energy expenditure.

Latest Patents

Kanemoto's most significant patent revolves around cyanotriazole compounds. This invention includes a specific cyanotriazole compound represented by a defined formula. The innovative aspect of this compound lies in its ability to stimulate citric acid cycle activity and improve hyperglycemia with minimal side effects. This makes it a promising candidate for treating or preventing various diseases and disorders, including diabetes, obesity, dyslipidemia, and cardiovascular diseases. The compound’s safety profile further enhances its therapeutic potential.

Career Highlights

Naohide Kanemoto is affiliated with Otsuka Pharmaceutical Company, Limited, where he has dedicated his efforts to developing novel pharmacological compounds. His work exemplifies the critical intersection of scientific research and practical application, aiming to improve patient outcomes through innovative therapies.

Collaborations

During his career, Kanemoto has collaborated with esteemed colleagues such as Seiji Sato and Satoshi Matsuda. These collaborations reflect a strong emphasis on teamwork and combined expertise, further enriching the quality of research and innovation produced within the company.

Conclusion

Naohide Kanemoto’s contributions to the field of pharmaceuticals, particularly through his work with cyanotriazole compounds, signify a meaningful advancement in the treatment of metabolic disorders. His collaborative spirit and commitment to innovation within Otsuka Pharmaceutical Company, Limited underscore the importance of teamwork in the quest for improved health solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…